Silence Therapeutics (SLN) Gross Margin: 2020-2025
Historic Gross Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 59.75%.
- Silence Therapeutics' Gross Margin rose 20267.00% to 59.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.32%, marking a year-over-year increase of 6136.00%. This contributed to the annual value of 72.70% for FY2024, which is 1336.00% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Gross Margin is 59.75%, which was down 3.71% from 62.05% recorded in Q2 2025.
- Silence Therapeutics' 5-year Gross Margin high stood at 91.95% for Q4 2024, and its period low was 322.12% during Q2 2024.
- Moreover, its 3-year median value for Gross Margin was 60.14% (2023), whereas its average is 9.12%.
- In the last 5 years, Silence Therapeutics' Gross Margin tumbled by 39,103bps in 2024 and then soared by 38,418bps in 2025.
- MRQ analysis of 5 years shows Silence Therapeutics' Gross Margin stood at 40.19% in 2021, then plummeted by 53bps to 19.01% in 2022, then surged by 89bps to 35.87% in 2023, then skyrocketed by 156bps to 91.95% in 2024, then plummeted by 35bps to 59.75% in 2025.
- Its last three reported values are 59.75% in Q3 2025, 62.05% for Q2 2025, and 61.97% during Q1 2025.